Clarence Ahlem
Directeur des opérations chez NeurMedix, Inc.
Fortune : 16 939 $ au 31/05/2024
Profil
Clarence Ahlem currently works at NeurMedix, Inc., as Chief Operating Officer.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
BIOVIE INC. CLASS A
0,06% | 16/02/2023 | 37 148 ( 0,06% ) | 16 939 $ | 31/05/2024 |
Postes actifs de Clarence Ahlem
| Sociétés | Poste | Début |
|---|---|---|
NeurMedix, Inc.
 NeurMedix, Inc. Pharmaceuticals: MajorHealth Technology NeurMedix, Inc. is a clinical-stage biopharmaceutical company that develops products for the treatment of neurological and neuro-degenerative disorders and certain cancers. NeurMedix is based in San Diego, CA, and was founded by Terren S. Peizer, who has been the CEO since incorporation. The private company's product candidates have completed several pre-clinical and clinical studies, indicating its broad anti-inflammatory effect without evidence of immunosuppression. NeurMedix has invested over $85 million in developing NE3107, and its focus is on diseases with significant unmet medical needs and commercial potential. The company plans to enter clinical trials for the treatment of Parkinson's disease and several oncological indications later this year. | Directeur des opérations | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
NeurMedix, Inc.
NeurMedix, Inc. Pharmaceuticals: MajorHealth Technology NeurMedix, Inc. is a clinical-stage biopharmaceutical company that develops products for the treatment of neurological and neuro-degenerative disorders and certain cancers. NeurMedix is based in San Diego, CA, and was founded by Terren S. Peizer, who has been the CEO since incorporation. The private company's product candidates have completed several pre-clinical and clinical studies, indicating its broad anti-inflammatory effect without evidence of immunosuppression. NeurMedix has invested over $85 million in developing NE3107, and its focus is on diseases with significant unmet medical needs and commercial potential. The company plans to enter clinical trials for the treatment of Parkinson's disease and several oncological indications later this year. | Health Technology |
